GlassScriptPhysician profile
Christine Ellen Shaffer
NPI 1710649181
$6,460.19
in general payments reported to CMS, 2019-2025
23 companies · $1,565 in 2025
The $1,565 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $167 · 2022: $1,673 · 2023: $1,444 · 2024: $1,611 · 2025: $1,565.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,459 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,458.65 |
| Education | $160.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,899.47 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $559.42 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Janssen Biotech, INC. | $503.23 | 2022-2025 | Tremfya |
| Incyte Corporation | $413.88 | 2021-2025 | Opzelura |
| Regeneron Healthcare Solutions, INC. | $373.79 | 2021-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $348.55 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $342.18 | 2023-2024 | Vtama |
| Pfizer INC. | $302.91 | 2022-2025 | |
| Ucb, INC. | $280.14 | 2021-2025 | Bimzelx, Cimzia |
| Amgen INC. | $242.86 | 2022-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $229.79 | 2022-2025 | |
| Genzyme Corporation | $183.52 | 2021-2025 | |
| Lilly USA, LLC | $164.48 | 2022-2024 | Taltz, Olumiant, Ebglyss |
| Arcutis Biotherapeutics, INC. | $157.30 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $136.94 | 2024-2025 | Adbry, Anzupgo |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $85.70 | 2024-2025 | Nemluvio |
| Paratek Pharmaceuticals, INC. | $75.46 | 2022 | |
| Kyowa Kirin, INC. | $41.21 | 2022 | |
| Helsinn Therapeutics (U.S.), INC. | $33.00 | 2023-2025 | Valchlor |
| Merz North America, INC. | $29.90 | 2025 | |
| Organon LLC | $22.58 | 2025 | Vtama |
| Alexion Pharmaceuticals, INC. | $20.57 | 2025 | Koselugo |
| Fresenius Kabi USA, LLC | $13.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Shaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.